Localizing the Global

Testing for Hereditary Risks of Breast Cancer

Datos Bibliográficos

ID5197856
AutoresIlana Löwy (0000-0001-6963-0578, Inserm), Jean-Paul Gaudillière (0009-0008-6984-2667, Institut National de Recherche en Santé Publique), Jean Paul Gaudillière (Inserm)
Año2008
Volumen33
Número3
Páginas299-325
Fecha de publicación2008-05-01
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaScience Technology & Human Values (JOURNAL)
Identificadores de la revistaISSN: 0162-2439 • E-ISSN: 1552-8251
EditorialSAGE Publications Inc (PUBLISHER)
DOI10.1177/0162243907306855
OpenAlexW2120107382
IdiomaEN
Citas recibidas30
Referencias citadas51

Tests for hereditary predispositions to breast and ovarian cancer have figured among the first medical applications of the new knowledge gleaned from the Human Genome Project. These applications have set off heated debates on general issues such as intellectual property rights. The genetic diagnosis of breast cancer risks, and the management of women "at risk" has nevertheless developed following highly localized paths. There are major differences in the organization of testing, uses of genetic tests, and the follow up of patients. This article studies testing practices and ways of managing breast cancer risk in France and compares them with those in the United States and United Kingdom. It shows how the complex interaction between global and local factors shapes the multiple meanings assumed by the phrase cancer risk

Breast cancer · Cancer · Genealogy · Genetic testing · Intellectual property · Phrase · Political science · Biomedical Ethics and Regulation · BRCA gene mutations in cancer · Computer Science · Ethics in Clinical Research · History · Law · Medicine · Artificial Intelligence